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Dear Sir:
Concomitant occurrence of acute myocardial infarction (MI) 
and stroke is infrequently encountered in emergent patients. 
Acute MI within the previous 3 months is considered a relative 
contraindication for therapy with alteplase or intravenous tissue 
plasminogen activator (IV rtPA).1 The use of IV rtPA for stroke 
in patients with a recent MI is associated with an increased risk 
of cardiac rupture, secondary to breakdown of the existing fibrin 
clot within the necrotic myocardium and/or degradation of col-
lagen2. Whether it is appropriate to perform thrombolysis in an 
emergent patient with concomitant ischemic stroke and MI re-
mains a matter for debate. 
A 44-year-old Caucasian man with a past history of binge drink-
ing and heavy smoking since childhood, presented to the emer-
gency department (ED) with a history of sudden onset of focal 
neurologic deficits, which had stared 1 hour previously. Neuro-
logical examination revealed dysarthria, left-sided homonymous 
hemianopia, facial central paresis, hemiparesis, and hemineglect 
(National Institutes of Health Stroke Scale [NIHSS] score, 11). 
His general examination was unremarkable. Blood pressure was 
110/70 mmHg, temperature was 36.8°C, and pulse was 61 bpm. 
There was no jugular venous distension. He also complained of 
an intermittent vague ache in the anterior thoracic region and left 
shoulder, which had been present for the preceding 48 hours. The 
patient’s electrocardiogram showed signs compatible with inferior 
MI with 2:1 atrioventricular block (Figure 1A). Cardiac troponin 
I level was elevated at 16.045 ng/mL (normal value, ≤ 0.04 ng/
mL). Emergent bedside transthoracic echocardiography showed 
the presence of inferior wall hypokinesis with good left ventricular 
systolic function. Computed tomography brain scan (brain CT) 
showed early signs of ischemia in the territory of the right mid-
dle cerebral artery (Figure 1B). 
IV t-PA (0.9 mg/kg over 1 hour, total dose 80 mg) was admin-
istered 2 h after stroke onset. The patient’s condition improved 
with thrombolysis (NIHSS score, 4). Approximately 10 hours 
after thrombolysis, he developed persistent bradycardia (40-50 
bpm) and hypotension (100-90 mmHg systolic, 40-60 mmHg 
diastolic), requiring treatment with volume expanders. Trans-
thoracic echocardiography revealed expansion of the MI to the 
right ventricle, without cardiac tamponade or depression of sys-
tolic function. Brain CT was repeated after 24 hours and showed 
the presence of ischemia in the cortical territory of the right mid-
dle cerebral artery (Figure 1C). Results of the remaining investi-
gations, including a metabolic panel (glucose levels, hemogram, 
blood coagulation times, ionogram, renal function, hepatic en-
zymes), were normal. The patient was transferred to the intensive 
care unit after successful resuscitation for ventricular fibrillation. 
He remained in the intensive care unit for 2 consecutive weeks, 
during which time he had several medical complications, includ-
ing refractory malignant arrhythmias with a recurrent need for 
resuscitation. Brain CT was repeated 8 days after the stroke and 
showed 2 new lesions in the posterior cerebral artery territory 
(Figure 1D). On discharge from the ICU, he had Psychomotor 
slowing, left-sided hemiparesis/hemihypesthesia and mild ap-
pendicular ataxia (NIHSS score, 9). Six months after the stroke, 
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he resumed his normal life (Rankin 2).
The inclusion of MI as a relative or absolute contraindication 
for IV rtPA in acute stroke is not evidence-based.1,2 Although car-
diac wall rupture and tamponade are very rare in patients present-
ing acute stroke and MI, these complications may constitute a 
major barrier for IV rtPA in such patients.2 Factors known to be 
associated with an increased risk of cardiac wall rupture and tam-
ponade include older age, female sex, large anterior MI, longer 
time from symptom onset to thrombolysis, infarct size, transmu-
ral extent, and pericardial involvement.3,4 The overall frequency 
of these complications is approximately 1% in patients treated 
with thrombolysis for acute MI.3 However, in comparison to 
controls, with the exception of patients older than 75 years, the 
occurrence of and the risk of mortality from cardiac rupture is 
not increased after treatment of acute MI with rtPA.3-5
There are no evidence-based guidelines for the management 
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Figure 1. (A) Electrocardiogram showing sinus rhythm, with 2:1 conduction block; two p waves (blue arrows) and one QRS wave (blue circle) are shown. ST elevation 
is visible in leads II, III, and aVF (red arrows), with ST depression in leads I and aVL (white arrows). (B) Brain CT showing early signs of acute stroke (insular ribbon 
sign and hemispheric sulcus effacement) in the right MCA territory. (C) Established stroke in the cortical territory of the right MCA. (D) Additional bilateral ischemic 
stroke in the posterior territory.
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of patients with concomitant acute MI and acute stroke, nor are 
there published clinical studies addressing the decision-making 
process in such cases. Depending on the clinical picture, physi-
cians may focus on the management of either the stroke or the 
MI. Obviously, independent management of one thrombosed 
territory will delay the treatment of the other vascular bed. Al-
though superior to thrombolysis for acute MI,6 primary percu-
taneous coronary intervention would delay rtPA for stroke, in-
creasing the risk of severe neurological disability in our case. 
Furthermore, intravenous heparin bolus during, and dual anti-
platelet therapy (aspirin plus clopidogrel) following coronary 
angioplasty, would potentiate the risk of hemorrhagic complica-
tions related to rtPA for stroke. Mechanical thrombectomy for 
acute stroke, a procedure that is not available in most hospitals 
including ours, could theoretically be combined with percuta-
neous coronary intervention. While we did not find any single 
report of such combined intervention, some authors believe 
that in the presence of acute ischemic emergent conditions af-
fecting different territories or organs, intravenous thrombolytic 
therapy is a reasonable option.7 
In a patient without demographic risk factors for cardiac tam-
ponade, we decided to offer thrombolysis in a balanced attempt 
to treat both myocardial and brain infarction, after excluding 
any relevant change on bedside transthoracic echocardiography. 
In conclusion, given the current knowledge limitations, treat-
ment decisions in cases of concomitant acute MI and acute isch-
emic stroke should be individualized. The delicate balance be-
tween the presence or absence of risk factors for cardiac tam-
ponade and the potential cardiac or neurological disability may 
guide the clinician in such a difficult scenario. Alteplase should 
probably not be avoided in eligible patients with ischemic stroke 
and MI in the absence of the aforementioned risk factors for car-
diac complications associated with intravenous thrombolysis.
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